Sun Pharma Q1 Results: Net profit rises 40.2% to ₹2,835.6 crore, revenue up 6%

The stock was trading 0.2% higher at ₹1,723.4 on the NSE. It was trading at ₹1,721.7, up 0.2%, on the BSE

Sun Pharma Q1 results

The speciality generic pharmaceutical company reported a consolidated net profit of ₹2,835.6 crore for the latest June quarter, up 40.2% year-on-year (YoY) from ₹2,022.5 crore in the year-ago period.

Revenue from operations increased 5.9% to ₹12,652.7 crore in Q1 FY25, compared to ₹11,940.8 crore in the corresponding period last year.

Sun Pharma's EBITDA (earnings before interest, taxes, depreciation, and amortisation) stood at ₹3,607.6 crore (including other operating revenues), up 8.3% YoY. The EBITDA margin for the April-June quarter of FY25 was 28.5% vs 27.9% during Q1 FY24.

Formulation sales in India were ₹4,144.5 crore, up by 16.4%. "India formulation sales accounted for about 33.1% of total consolidated sales," the company said in an exchange filing.

Formulation sales in the United States were $466 million, accounting for more than 31.1% of total consolidated sales.

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said, "Sun has recently attained several milestones with the approval of Leqselvi in the US, the filing of Nidlegy in Europe, and the completion of the acquisition of Taro minority shares. These steps advance our innovative and generic business offerings and will help us serve patients better."

The stock has gained 36.6% year-to-date and has risen 50.6% in the past year.